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Abstract
Opportunistic infections (OIs) cause significant morbidity/mortality in human immunodeficiency 
virus (HIV)‑infected individuals globally. Disparities between high‑income countries (HICs) 
and low/middle‑income countries (LMICs) in the magnitude of HIV‑related OIs in pre‑highly 
active antiretroviral therapy (HAART) populations was reviewed, and HAART‑induced 
decline in OIs was further compared between the two settings. Studies published in English 
from onset of HIV epidemic up to December 2013 were searched in PubMed, Google, Google 
Scholar, and African Journal online. An article was included if (a) the study was conducted 
in HIC or LMIC, (b) the age of the participants was ≥12 years, (c) the HAART status of the 
participants was stated, and (d) various types of OIs were investigated. In predominantly 
pre‑HAART populations, the incidence and prevalence of overall HIV‑related OIs in HIC 
ranged from 5.5 to 50.0 per 100 person‑years (PY) and 27.4–56.7%, respectively. In LMIC, 
the respective overall incidence and prevalence of OIs were 12.2–93.9 per 100 PY and 
32.0–77.7%. Pneumocystis jirovecii pneumonia, candidiasis, Cytomegalovirus disease, 
Mycobacterium avium complex disease, and Kaposi’s sarcoma were the most frequent OIs in 
HICs while tuberculosis, candidiasis, chronic diarrhea, and cryptococcosis were predominant 
in LMICs. The introduction of HAART led to substantial reduction in the incidence of OIs 
with more impressive percentage decline in HICs (43–97%) compared to 30–79% in LMICs. 
Disparities in the magnitude of HIV‑related OIs between HICs and LMICs are evident both 
in the pre‑HAART and post‑HAART era. Efforts to optimize HAART‑induced decline in 
HIV‑related OIs should become a global health priority irrespective of prevailing socioeconomic 
circumstances.
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Introduction
The human immunodeficiency virus (HIV) infection 
and its progression to the acquired immune deficiency 
syndrome (AIDS) have significantly affected the global health 
statistics over the past three decades. Globally, there are an 
estimated 35.3 million people living with HIV (PLHIV), and 
2.3 million new HIV infections and 1.6 million AIDS deaths 
occur annually.[1] By far, the greatest impact of the disease has 
been in low- and middle-income countries (LMICs) where an 
estimated 90% of the global HIV-infected population live.[1]
The hallmark of HIV infection is immunosuppression which 
predisposes affected individuals to infections by unusual 
pathogens referred to as opportunistic infections (OIs). OIs 
constitute a major cause of morbidity and mortality in PLHIV, 
globally.[2-6] Over the three decades of the HIV epidemic, 
HIV-related OIs commonly reported in various populations 
include Pneumocystis jirovecii pneumonia (PJP) (previously 
called Pneumocystis carinii pneumonia), tuberculosis (TB), 
candidiasis, Cytomegalovirus (CMV) disease, Mycobacterium 
avium complex (MAC) disease, chronic parasitic diarrhea, 
toxoplasmosis, and cryptococcosis.[2,3,7-14] Findings of some studies 
suggest differences in the magnitude and types of HIV-related 
OIs seen in LMICs,[7-11] and high-income countries (HICs).[12-14]
Before the introduction of antiretroviral therapy (ART), 
progression to AIDS and premature death was the reality for 
HIV-infected individuals in both HICs and LMICs. During 
that period, AIDS-related deaths where overwhelmingly 
attributed to OIs. In the era of highly active ART (HAART), 
a significant decline in the magnitude of OIs as well as overall 
morbidity and mortality in HIV-infected populations have 
been demonstrated in various populations.[15-18] Nevertheless, 
available reports suggest that OIs remain an important cause 
of morbidity and mortality in PLHIV in the era of HAART in 
several populations.[19-21] Considering that access to HAART 
and optimization of antiretroviral treatment options have not 
been uniform among HIV-infected populations across various 
socioeconomic divides,[19] the positive impact of HAART in 
reducing the magnitude of HIV-related OIs may therefore have 
regional dimensions.
This review has three major objectives: First, to compare the 
overall incidence (or prevalence) of HIV-related OIs between 
HICs and LMICs in predominantly pre-HAART populations. 
Second, to highlight any disparities between LMICs and HICs in 
the frequency of individual OIs documented in available studies. 
Finally, to compare the impact of HAART on the magnitude 
of HIV-related OIs between the two socioeconomic settings.
Materials and Methods
Search strategy
Online databases and search engines including PubMed, 
Google, Google Scholar, and African Journal on-line were 
searched for articles published on HIV-related OIs from the 
onset of the epidemic up to December 31, 2013. Key words 
and expressions used for the search included “HIV-related 
opportunistic infections,” “HIV-related opportunistic 
diseases,” “HIV-associated opportunistic infections,” 
“HIV-associated opportunistic diseases,” “AIDS-related 
opportunistic infections,” “AIDS-related opportunistic 
diseases,” “AIDS-associated opportunistic infections,” 
“AIDS‑associated opportunistic diseases,” and “AIDS‑defining 
illness”. The search was limited to articles published in 
English. A total of 14,431 articles were initially identified. 
After elimination of duplicates and studies that were not 
relevant to OIs in the setting of HIV/AIDS, 2,183 studies 
remained. Available full articles or abstracts of these studies 
were scrutinized to identify those that met the inclusion criteria. 
References of relevant articles were also checked. After 
exclusion of articles that did not meet the inclusion criteria, 
77 articles that met the inclusion criteria were reviewed. The 
selection flowchart for papers reviewed is shown in Figure 1.
Selection criteria
Studies that met the following criteria were included: (a) Study 
was conducted in a setting (s) easily identifiable as HIC, 
LMIC as defined by the World Bank in 2013,[22] (b) age of the 
participants was ≥12 years, (c) the HAART status of the study 
population was stated, (d) the study investigated various types 
of OIs in an HIV-infected population rather than a single OI.
Ethical considerations
The author did not receive any funding for this review, and 
there are no personal, political, or academic competing 
interests. Accurate data extraction was ensured as much as 
possible. Extracted duplicate publications were deleted, and 




Not relevant to HIV-related OIs: 8,001
Abstracts assessed: 1,901
Did not meet inclusion criteria: 1,824
Articles reviewed: 77












Figure 1: Flow chart for selection of papers. HIC: High income country, 
LMIC: Low/middle-income country, OI: Opportunistic infection
Iroezindu: Disparities in HIV‑related opportunistic infections
6 Annals of Medical and Health Sciences Research | Jan-Feb 2016 | Vol 6 | Issue 1 |
included in the review. Articles that met the eligibility criteria 
were included in the review irrespective of whether their 
findings were positive or negative.
Terminologies
ART-naive population referred to those who did not receive 
any form of ART.
HAART population referred to individuals who received 
ART (of any duration) made up of three drugs from at least 
two antiretroviral classes irrespective of whether a protease 
inhibitor (PI) was used.
Bearing in mind that classification of HAART status as 
previously described by Detels et al.,[23] using the 1996 
cut-off calendar period (before 1996- pre-HAART; 1996 and 
beyond- post-HAART) may not be generalizable to several 
settings in LMICs that were yet to have established access 
to HAART around 1996, when the terms pre-HAART and 
post‑HAART were used for specific studies, the calender 
periods being referred to were highlighted.
Chronic diarrhea as used in this review referred to cases mainly 
caused by cryptosporidium and/or Isospora belli.
HIV-related (or HIV-associated) OI included both 
AIDS‑defining and non‑AIDS defining OIs. This general term 
was adopted to harmonize the differences among the studies. 
Some studies investigated for only AIDS‑defining OIs while 
others included non‑AIDS defining OIs. Among the studies that 
investigated for only AIDS‑defining OIs, various criteria were 
used such as CDC, 1987;[24] WHO, 1990;[25] CDC, 1993;[26] 
and WHO, 2005.[27]
Results
Seventy-seven publications met the study’s inclusion criteria. 
Twenty one studies were conducted in HICs while the 
remaining 56 were carried out in LMICs. In HICs, there were 
14 prospective cohort studies, 5 retrospective cohort studies, 
1 randomized control trial and 1 bidirectional study with 
prospective, and retrospective arms. In LMICs, 20 studies had 
a prospective cohort design, 14 were retrospective analysis, 
20 were cross-sectional studies, 1 was bidirectional (both 
prospective and retrospective arms), and 1 had both 
retrospective and cross‑sectional designs. The findings of these 
studies are highlighted below and summarized in Tables 1-3.
Overall magnitude of opportunistic infections
Tables 1 and 2 summarize the studies that reported the 
overall incidence or prevalence (respectively) of OIs among 
predominantly pre-HAART populations in both HIC and 
LMIC. The overall incidence of HIV-related OIs in various 
studies in the HIC of the United States of America, Western 
Europe, and Australia ranged from 4.5 to 50.0 per 100 
person-years (PY) of follow-up.[15-17,20,28-35] Fewer studies 
reported the overall prevalence of HIV-related OIs in HICs 
and found rates of 27 [1,493/5,451]–57 [228/402] %.[12,13,41] 
The majority of studies in HICs reported only the first episodes 
of HIV-related OIs[12,15-17,30-32,34,35] while others included any 
incident OI that occurred during the study.[13,28,33]
In LMICs of Asia, South/Central America, and sub-Saharan 
Africa, the overall incidence of HIV-related OIs was 
12.2–93.9 per 100 PY.[18,36-40] Several studies reported the 
overall prevalence of OIs in LMICs and the range was 
32.0 [66/207]–77.7 [136/175]%.[7-11,42-49] As was the case in 
HICs, most of these studies reported only the first HIV‑related 
OI events[7,9,10,18,36,38,39,41,44] while others included any incident 
OI that occurred during the study.[8,40,42,47]
Magnitude of individual opportunistic infections
The frequency or incidence of individual OIs reported in 
various HICs and LMICs are presented below on the regional 
basis. In each region, the frequency of individual OIs as a 
proportion of total OIs documented is presented first followed 
by reports of incidence rates for individual OIs where available.
North America
In a survey of 6682 HIV-infected patients spanning 1990–1994 
in the United States, 1883 died from OIs. The OIs that 
were most frequently experienced were PJP 45%, MAC 
disease 25%, CMV disease 23%, and esophageal/pulmonary 
candidiasis 22%.[2] The predominance of candidiasis (0.5–13.0 
per 100 PY), PJP (0.4–9.0 per 100 PY), MAC (0.3–7.0 
per 100 PY), CMV (0.2–7.0 per 100 PY), and Kaposi’s 
sarcoma (KS) (2.5 per 100 PY) among OIs that occurred in 
predominantly pre-HAART US cohorts was also highlighted 
by other studies that documented their incidence rates.[15,28,29,51]
Western Europe and Australia
The frequency of individual OIs reported in various studies 
in Europe was fairly reflective of the predominant pattern in 
HIC. The frequently reported OIs were: CMV (9–37%),[34,52,53] 
PJP (10–29%),[34,52,53] toxoplasmosis (2.1–37%),[34,52,53] 
candidiasis (8–23%),[34,52,53] KS (7–28%),[34,52,53] and MAC 
(8–17%).[34,52,53] TB (7–11%),[52,53] and cryptococcosis (7%)[52] 
were less frequently experienced.
The incidence of individual OIs in studies conducted in Europe 
and Australia were as follows: Toxoplasmosis (1.5–12.6 
per 100 PY),[16,33,54] PJP (1.5–11.4 per 100 PY),[16,17,33,35,54] 
candidiasis (1.7–11.0 per 100 PY),[16,17,33,35,54] MAC (0.37–9.5 
per 100 PY),[16,17,33,35,54] CMV (0.59–6.8 per 100 PY),[16,17,33,35,54] 
TB (0.64–3.6 per 100 PY),[16,33,35,54] and chronic diarrhea (0.6 
per 100 PY).[33]
Central and South America
In Central and South America, the frequently reported OIs 
included KS (5–47%),[46,55] candidiasis (12–44%),[11,46,56,57] 
TB (9–32%),[11,46,55-57] chronic diarrhea (3–33%),[11,46,56,57] 
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Table 1: Studies that reported overall incidence of opportunistic infections in predominantly pre‑highly active antiretroviral 
therapy populations in high and low/middle‑income countries




Remarks Study period OI incidence (/100 PY) 
High‑income 
countries
1996[28] USA, RCT n: 1530
Age: 31 (12-66) years ***
Male/female: 9:1
CD4 inclusion criteria: ≤300 cells/µl
Repeat OI events included
OI criteria: CDC, 1993
Randomized for monotherapy with zidovudine or 
didanosine
October 1989 to 
April, 1992





Age: 80% were 30-49 years
Male/female: 4:1
CD4 inclusion criteria: <100 cells/µl
OI criteria: not clearly stated
Likely all incident OIs
75% ART-naive or monotherapy in 1994; 94% on cART 
by June 1997
January 1994 to 
June 1997







CD4 inclusion criteria: None
OI criteria: Not clearly stated
Likely all incident OIs
58% on HAART by 1998





Only women without previous AIDS
CD4 inclusion criteria: None
Only first OI event after enrolment
OI criteria: CDC, 1993
Predominantly ART‑naive and non‑HAART populations
December 1989 
to June 2002







CD4 inclusion criteria: None
Only first OI event after enrolment
OI criteria: CDC, 1993
99% on non-HAART regimen before 1996 (defined as 
pre-HAART era)





n: 8070 (4231 beeween 1994-1997)
Age: 38 years*
Male/female: 4:1
CD4 inclusion criteria: None
Only first OI event after enrolment
OI criteria: CDC, 1993
1994-1997: 25% ART-naive, 46% non-cART, 29% cART
January 1994 to 
December 2007






Age: 38 (34-44) years**
Male/female: 7.6:1
CD4 inclusion criteria: None
Only first OI event after enrolment
OI criteria: CDC, 1993
Newer and cART commenced in 1995
January 1994 to 
December 1996




n: 1806 (286 before 1992)
Age: 32.3 (27.8-38.3) years**
CD4 inclusion criteria: None
Median CD4: 321 (120-520) cells/µl
Only first OI event after enrolment
OI criteria: CDC, 1993
Monotherapy was the only form of treatment before 
1992
1987-1998 27.4 per 100 PY 
(before 1992)
Contd...
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Table 1: Contd...








n: 2011 (1115 in January 1989)
Age: 31 (17-78) years***
Male/female: 3:1
CD4 inclusion criteria: ≤500 cells/µl
OI criteria: Not clearly stated
Any incident OI during follow-up
15% monotherapy, 50% dual therapy and 35% HAART 
in 1997
January 1989 to 
December 1997







CD4 inclusion criteria: None
Only first OI after enrolment
OI criteria: CDC, 1993




15.1 per 100 PY (in 
the 6 months before 
September 1995)
2000[34] 51 Centres 
across Europe 
(including Israel)
n: 7300 (3047 by January 1995)
Age: >16 years
CD4 inclusion criteria: <500 cells/µl
Median CD4: 166 (44-300) cells/µl
OI criteria: CDC, 1993
Only first OI after enrolment
HAART for the majority in January 1999
May 1994 to 
Spring 1999
30.7 per 100 PY (1994)






Patients wth known dates of seroconversion spanning 
1979-2000
Age: 28 (15-86) years***
Male/female: 4:1
CD4 inclusion criteria: None
Only first OI event after enrolment
OI criteria: European AIDS case definition, 1993
Dominanted by ART naive and non‑HAART  
populations
Data pooled in 
2001








Age: 34 (male); 28 (female) years*
Male/female: 6:1
CD4 inclusion criteria: None
Median CD4 (cells/µl)
197 (male), 413 (female)
Any incident OI during follow-up










Age: 32 (29-37) years**
Male/female: 1:1.4
CD4 inclusion criteria: None
CD4: 152 (25-348) cells/µl
Only first OI event after enrolment
OI criteria: Not clearly stated
23% had history of ART use as mono or dual therapy
July 2000 to 
October 2004







Age: 39.9 (9.3 years)****
Male/female: 2.6:1
CD4 inclusion criteria: At least one CD4 at least 
≤100 cells/µl
Only first OI event after enrolment
OI criteria: CDC, 1993





51 per 100 PY
Contd...
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PJP (13–29%),[11,46,55-57] toxoplasmosis (4–18%),[11,55-57] and 
cryptococcosis (5–14%).[11,55-57] CMV (2–5%),[11,46,55-57] and 
MAC (1%)[11,56,57] were infrequent conditions. None of the 
available studies documented incidence rates for individual 
OIs.
Asia
The OIs that were more frequently documented in 
Asia included candidiasis (1–88%),[3,7,10,18,43-45,58-67] TB 
(11.3–71%),[3,7,8,10,42,44,45,58,59,62-66,68-71] chronic diarrhea 
(0.3–47%),[3,7,8,10,43-45,58-67,69] CMV (1–45%),[3,7,10,18,43-45,58-64,67,71] 
and cryptococcosis (2–38%).[3,7,8,10,18,42,44,58,59,62-64,66,67] 
Other conditions were less frequently reported including 
P J P ( 1 – 2 3 % ) , [ 3 , 8 , 1 0 , 4 2 , 5 8 , 5 9 , 6 2 , 6 3 , 6 7 , 6 8 ]  t o x o p l a s m o s i s 
(1–11%),[3,8,10,18,58,64,66,67] and MAC (2–3%).[64,65] KS was not 
documented in the available studies.
The incidence of individual HIV-related OIs was documented 
by Ghate et al.[36] in 457 cohorts in India. TB was the most 
common condition with an incidence of 15.4 per 100 PY, 
followed by candidiasis (11.3 per 100 PY). Cryptococcal 
meningitis was relatively less common at 1.7 per 100 PY 
while the incidence of each of PJP, CMV, and toxoplasmosis 
were <1.7 per 100 PY.
Sub‑Saharan Africa
In sub-Saharan Africa, the frequency of individual 
OIs were as fol lows: TB (13–64%), [6,9,22,47-49,72-84] 
candidiasis (11–42%),[9,48,49,75-79,81,83] cryptococcosis 
(1–39%),[9,22,47,49,74-79,81,83-85] chronic diarrhea (3–35%),[9,22,47,49,75-81] 
toxoplasmosis (2–24%),[9,47,78-81] KS (1–18%),[9,22,49,72,77,78,82] 
CMV (1–18%),[9,75,77,82] and PJP (0–5%).[22,47,76-81] MAC was 
not documented in any of the available studies in sub-Saharan 
Africa. None of the available studies documented incidence 
rates for individual OIs.
Impact of highly active antiretroviral therapy on the 
magnitude of human immunodeficiency virus‑related 
opportunistic infections
Impact on incidence or prevalence of overall 
opportunistic infections
Since the introduction of HAART, a significant decline in 
AIDS progression and the burden of OIs have been observed 
globally.[8,9,16,83-86] Table 3 summarizes the findings of cohort 
studies that documented the effect of HAART on the overall 
incidence or prevalence of HIV-related OIs.
In the HICs of North America, Western Europe and 
Australia, the introduction of HAART led to the significant 
decline of about 42.8–96.6% in the overall incidence of 
HIV-related OIs.[14-17,20,30-35] In the LMIC of South/Central 
America, Asia and sub-Saharan Africa, the decline in the 
overall incidence of OIs was about 30.0–79.0%.[11,18,36,37,39] 
In three studies that reported the effect of HAART on the 
overall prevalence of OIs in LMIC, the percentage reduction 
was about 38.3–47.0%.[8,9,46,50] As shown in Table 3, the 
HAART-induced decline in the overall incidence of OIs 
in Ivorian cohorts was seen for the first, second and third 
events with the percentage decline in OI events higher for 
subsequent events.[39] De Beaudrap et al.[9] in Senegal found 
Table 1: Contd...









Age: 35 (18-67) years*****
Male/female: 2.6:1
CD4 inclusion criteria: None
CD4: 492 (332) cells/µl
OI criteria: CDC, 1987
Only first OI event after enrolment
ART with multiple drugs commenced November, 1996
1986-1997 12.2 per 100 PY




Age: 31 (26-7) years**
Male/female: 1:2.3
No CD4 inclusion criteria
CD4: 290 (161-477) cells/µl
OI criteria: Not clearly stated
Reported OI incidence in sequence
OI events stated for ART-naive only
1996-2003 40.6 per 100 PY 
(1st events)
68.4 per 100 PY 
(second events)
93.9 per 100 PY 
(3rd events)




Age: 31.3 (8.9) years****
Male/female: 1:1.1
No CD4 inclusion criteria
Any incident OI after enrolment
OI defined by WHO, 1990
ART naive
1992-2000 21.3 per 100 PY
†15Values were converted from incidence rates per 1000 person years of follow-up to 100 person years of follow-up, Age: *Median, **Median (IQR), ***Median (range), ****Mean (SD), 
*****Mean (range), ******Mean. n: Sample size, AIDS: Acquired immunodeficiency syndrome, ART: Antiretroviral therapy, c-ART: Combination antiretroviral therapy, CDC: Center for disease 
control and prevention, HAART: Highly active antiretroviral therapy, MSM: Men who sleep with men, OIs: Opportunistic infections, WHO: World Health Organization, SD: Standard deviation, 
IQR: Interquartile range, RCT: Randomized controlled trial, PY: Person years
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Table 2: Studies that reported overall prevalence of opportunistic infections in predominantly pre‑highly active 
antiretroviral therapy populations in high and low/middle‑income countries
Study, year of publication Setting and 
design
Remarks Study period OI prevalence (%)
High‑income countries
1998[13] USA, prospective 
cohort
n: 2081
Age: 35 (30-41) years**
Male/female: 2:1
No CD4 inclusion criteria
Median CD4: 264 cells/µl
Any incident OI after enrolment
Criteria: CDC, 1993
Pre‑HAART era





n: 1003 (402 in 1992)
MSM
Age: 38 years*
CD4 inclusion criteria: <200 cells/µl
Median CD4: 68 (63-73) cells/µl
Only first OI event for each year
OI criteria: CDC, 1993
27% ART-naive, 67% monotherapy 
in 1992
January 1992 to 
March 1997
56.7 (1992)
2007[41] USA, prospective 
cohort
n: 5451






Age: 31 (28-57) years**
Male/female: 3:1
CD4 inclusion criteria: None
Only first OI events
OI definition: Modified CDC, 1993
ART‑naive
January 1997 to 
June 2000
32
2006[42] India, prospective 
cohort
n: 438
Age: 77.9% were 20-40 years, 
19.9% were >40 years
Male/female: 4.2:1
CDC inclusion criteria: None
Only first OI events






2011[10] India, prospective 
cohort
n: 108
Age range: 21-50 years
Male/female: 2:1
CD4 inclusion criteria: None
Reported prevalence for OI events 
at baseline








Age range: 9-66 years, 96.1%# 
were>20 years
Male/female: 2:1
CD4 inclusion criteria: None
OI criteria: CDC, 1993













Only first OI events
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Table 2: Contd...
Study, year of publication Setting and 
design





Age: 35.4 (16-60) years*****
Male/female: 3.5:1
CD4 inclusion criteria: None
CD4: 131 (range 2-500) cells/µl
Likely only first OIs events
OI crieria: CDC, 1993
18% on ART including mono and 
dual therapy





n: 1044 (n: 175 in period 1)
Age: 34 (15-75) years, period 1***
CD4 inclusion criteria: None
CD4: 28 (1-762) cells/µl
Any incident OIs events in period 1
OI criteria: CDC, 1993
59% were ART-naive at enrolment 




Period 1: June 










CD4 inclusion criteria: None
OI criteria: Not clearly stated
Not clear if only first OI events
Pre‑HAART era








36% had CD4 <200 cells/µl
OI criteria: CDC, 1993





2012[47] South Africa, 
retrospective cohort
n: 382
Age: 37 (31-44) years**
Male/female: 1.1:1
CD4 inclusion criteria: <200 cells/µl
CD4: 33 (12-78) cells/µl
Only first OI events








Age range: 15-55 years
Male/female: 3:2
CD4 inclusion criteria: None
Only first OI events at enrolment








Age: 35 (8) years****
Male/female: 1:1.3
CD4 inclusion criteria: None
Median CD4: 88 (12-522) cells/µl
Only first OI events at enrolment
OI criteria: CDC, 1993
ART‑naive
October 2009 to 
November 2010
56.7
†15Values were converted from incidence rates per 1000 person years of follow-up to 100 person years of follow-up, Age: *Median, **Median (IQR), ***Median (range), ****Mean (SD), 
*****Mean (range), ******Mean, #Study was included in the review despite age range of 9-66 years because 96.1% of patients were >20 years and the remaining 3.9% of patients included 
those who were 12-20 years. n: Sample size, AIDS: Acquired immunodeficiency syndrome, ART: Antiretroviral therapy, CDC: Center for disease control and prevention, HAART: Highly active 
antiretroviral therapy, MSM: Men who sleep with men, OIs: Opportunistic infections, WHO: World Health Organization, SD: Standard deviation, IQR: Interquartile range, PY: Person years
that the overall incidence of OIs dropped from 20.5 per 
100 PY in the 1st year of HAART to 4.3 per 100 PY in 
the 4th year post-HAART. However, unlike what was seen 
in several other populations that observed a progressive 
decline in OIs when patients on HAART were followed up 
on a long-term basis, the incidence of OIs in the Senegalese 
cohorts began to increase by 5% per month after the 4th year 
of HAART.
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Table 3: Studies that documented the effect of highly active antiretroviral therapy on the overall incidence or 
prevalence of human immunodeficiency virus‑related opportunistic infections in high and low/middle‑income 
countries
Study, year of 
publication
Setting Design Overall OI incidence (per 100 PY) or prevalence (%) Percentage 
of decline in 
OI incidence 
or prevalence
ART‑naive or pre‑HAART Post‑HAART
High‑income 
countries
1998[20] USA Prospective cohort 
(1994-1996) (n=1255)
50 per 100 PY 
(1994/1995)
28.6 per 100 PY 
(1996)
42.8
2010[15] USA Prospective cohort 
(1994-2007) (n=870)
8.9 per 100 PY† 
(1994-1997)
0.3 per 100 PY† 
(2003-2007)
96.6
2009[31] USA Prospective cohort 
(1984-2007) (n=614)
7.55 per 100 PY 
(before 1996)
2.08 per 100 PY 
(1996-2007)
72.5




4.52 per 100 PY 
(before February 1994)
1.22 per 100 PY 
(Auguest 1996-1997)
73.0
1998[32] Canada Prospective cohort 
(1994-1996) (n=2533)
8.0 per 100 PY (1994) 2.2 per 100 PY 
(1996)
72.5





12.93 per 100 PY† 
(within 3 months of 
HAART)
1.32 per 
100 PY† (3 years 
post-HAART)
89.8





8.02 per 100 PY† 
(1994-1996)
2.53 per 100 PY† 
(1997-2000)
68.5
1999[17] England Prospective cohort 
(1987-1998) (n=1806)
27.4 per 100 PY 
(on or before 1992)
6.9 per 100 PY 
(1997)
74.8





30.7 per 100 PY (1994) 2.5 per 100 PY 
(1998)
91.9
1999[16] Switzerland Prospective cohort 
(1995-1997) (n=2410)
15.1 per 100 PY 
(6 months before HAART)




2003[33] Spain Prospective cohort 
(1989-1997) (n=1115)
36.4 per 100 PY 
(1989-1991)
14.6 per 100 PY 
(1997)
59.9
1997[12] Germany Prospective cohort 
(1992-1997) (n=1003)
56.7% (1992) 20.7% (1996) 64.7
Low/middle‑ 
income countries
2011[18] Thailand Prospective cohort 
(2000-2004) (n=704)
19.1 per 100 PY 
(pre-HAART)
8.2 per 100 PY 
(post-HAART)
57.1
2009[36] India Prospective cohort 
(2002-2004) (n=457)
37.3 per 100 PY 23.9 per 100 PY 35.9
2002[37] Brazil Bidirectional cohort 
(1997-1999) (n=79)
51.0 per 100 PY 
(pre-HAART)
29.0 per 100 PY 
(post-HAART)
43.1
2010[9] Senegal Prospective cohort 
(1998-2008) (n=404)
20.5 per 100 PY 
(1st year post-HAART)
4.3 per 100 
PY (4th year 
post-HAART)
79.0
2007[39] Cote d’Ivoire Prospective cohort 
(1996-2003) (n=608)
40.6 per 100 PY 
(1st OI event)
68.4 per 100 PY 
(2nd OI event)
93.9 per 100 PY 
(3rd OI event)
28.4 per 100 PY 
(1st OI event)
39.4 per 100 PY
(2nd OI event)














Peru Retrospective cohort 
(1994-2003)
32.6% (n=92) 20.0% (n=564) 38.7
2006[8] Taiwan Prospective cohort 
(n=1044)
77.1% (1994-1997) 47.6% (2000-2004) 38.3
†15Values were converted from Incidence rates per 1000 person years of follow-up to 100 person years of follow-up, n: Sample size, HAART: Highly active antiretroviral therapy, OI: Opportunistic 
infection, PY: Per year
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Magnitude of individual opportunistic infections in the 
post‑highly active antiretroviral therapy era
Generally, the magnitude (incidence or prevalence) of individual 
OIs among HIV cohorts post-HAART was reported by few 
studies. In HICs, the cohort studies that reported incidence 
of individual OIs post-HAART found the following rates per 
100 PY: Candidiasis 1.0–5.7,[16,17,33,35] MAC 0.6–2.7,[16,17,33,35] 
CMV 0.6–5.1,[16,17,33,35] PJP 0.2–4.4,[16,17,33,35] KS 0–2.3,[16,17,33,35] 
TB 0.2–2.6,[16,33,35] toxoplasmosis 0.2–1.8,[16,33,35] and 
cryptococcosis 0.6.[33] The frequency of individual OIs in HICs 
reported in two cohort studies were: CMV 1.8–7.7%,[15,34] PJP 
3.9–11%,[15,34] MAC 2.5–6.2%,[15,34] candidiasis 5.4–19%,[15,34] 
KS 1.2–8%,[15,34] TB 0.8–1.9%,[15,34] toxoplasmosis 0.5–1.3%,[15] 
and chronic diarrhea 0.8–2%.[15]
In four cohort studies, the following frequency of individual 
OIs among HIV-infected patients post-HAART in LMICs was 
found: TB 13.0–38.2%,[8,9,11,18] candidiasis 11.0–23.1%,[8,9,18] 
cryptoccosis 0–20.6%,[8,9,11,18] CMV 0–23.1%,[8,9,11,18] PJP 
0–29.5%,[8,9,11,18] KS 0–5.2%,[8,9] MAC 15.4–18.2%,[8] and 
toxoplasmosis 0–8.8%.[8,9,11,18]
Retention in human immunodeficiency virus care
Retention in HIV care is required for optimal clinical outcomes 
including reducing the magnitude of OIs. Available literature 
shows that definitions of retention in HIV care are rather 
heterogenous. According to the WHO, “Retention in HIV care” 
can be defined from the moment of initial engagement in care, 
when a person with HIV is linked successfully to services, to 
assessment for eligibility, initiation on ART, and retention in 
lifelong ART care.[87] However, in other studies and reports, 
it sometimes includes the period from diagnosis to successful 
linkage to care.[87]
Some studies in Western countries have assessed retention in 
care from such comprehensive perspectives. In a meta-analysis 
of 28 US studies with a total of 75, 655 HIV-diagnosed persons, 
it was reported that 59% of them, regardless of the length 
of time since diagnosis, were retained in care.[88] Retention 
in care was defined regarding multiple HIV medical care 
visits averaged across the assessment intervals. The estimate 
increased to 62% after omitting the two studies that had long 
assessment intervals of 3 and 5 years. The percentage of 
HIV-diagnosed persons retained in care was higher in studies 
conducted before 2003 (62%) than in studies conducted in 
2003 or more recently (42%).[88]
In the United Kingdom, the 12-month retention rate of all 
72,840 adults seen for HIV care in 2011 was 95%.[89]
In HIV treatment programs in resource-limited settings, 
retention in care has been defined as “patients known to be 
alive and on ART at the end of a follow-up period either at the 
same facility or formally transferred out to another ART unit 
and thus assumed to be on therapy.”[90,91] A large systematic 
review in 2007 that surveyed 32 publications on 33 cohorts 
comprising 74,289 patients in 13 countries reported a plausible 
mid-point estimate of retention 2 years after ART initiation of 
50% among HIV-infected patients on ART in Africa.[90] The 
analysis was updated in 2010 using an additional 39 cohorts 
of 226, 307, and it was found that the 24-month retention rate 
was 70.0%.[92]
Considering that most reports of retention in HIV care are 
based of clinic perspectives, it is likely that patients who 
are lost to follow-up have been assumed to have disengaged 
from care. However, in the setting of rapid ART scale-up and 
decentralization of care, this assumption may not always be 
true.[93] Some studies in Africa have shown that 50–55% of 
HIV-infected patients on ART who were lost to follow-up and 
found to be alive following contact tracing were still in care 
elsewhere.[94,95]
So far, there is a paucity of literature on long-term retention 
on ART (after 24 months), making this an important area for 
further study, especially in the light of recent changes in the 
WHO treatment guidelines, recommending treatment initiation 
at ≤500 cells/µl.
Discussion
In this review, the magnitude of HIV-related OIs in 
predominantly pre-HAART populations in both HIC and LMIC 
were described, and the percentage decline in the magnitude 
of OIs following the introduction of HAART was further 
highlighted in the two socioeconomic settings. The incidence 
or prevalence of overall HIV-related OIs was generally high in 
predominantly pre-HAART populations in both settings, but 
LMIC appeared to have higher OI incidence and prevalence. 
There were also disparities in the types of OIs predominant 
in each socioeconomic setting. While PJP, candidiasis, CMV 
disease, MAC disease, KS, and occasionally toxoplasmosis 
were predominant in HICs; TB, candidiasis, chronic diarrhea, 
and cryptococcosis were consistently more frequent in LMICs. 
Substantial reductions in the overall incidence or prevalence of 
OIs were documented following the introduction of HAART 
both in HICs and LMICs, but the percentage decline appeared 
more impressive in HICs.
There are a number of reasons for the apparent disparities 
in HIV-related OIs between HICs and LMICs. First, the 
methodological differences in the various studies reviewed 
could account for this. While the majority of the findings 
of HICs were based on the large prospective cohort studies, 
studies in LMICs mainly involved prospective or retrospective 
cohorts, or some cross-sectional studies with relatively smaller 
sample sizes. There were also some subtle differences in the 
definition of diseases selected for inclusion as OI in the various 
studies. In some studies, there were immunological criteria for 
inclusion, and this would strongly influence the spectrum of OIs 
since certain OIs are more commonly encountered with more 
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severe degrees of immunosuppression. There is overwhelming 
evidence that low baseline CD4+ cell count[16,36,54,64,96-99] and 
low CD4+ cell count during ART[16,29,100] are strong risk factors 
for OIs both in HICs and LMICs.
Beyond issues that bother on methodology, it has been shown 
that geographical differences may have a role to play in the 
reported incidence of HIV-related OIs.[54] This may explain 
why PJP and KS appeared relatively more frequent in Central/
South America than the other LMICs of Asia and sub-Saharan 
Africa. Nevertheless, the apparent rarity of MAC, CMV, and 
sometimes PJP in LMICs possibly raises concern on the role 
of local diagnostic capacity in the magnitude of reported OIs. 
The fact that a good number of centers in LMICs, especially 
sub‑Saharan Africa do not have sufficient diagnostic facilities 
for these three conditions should be borne in mind before 
drawing strong inferences on the burden of these OIs in LMICs.
The role of racial factors in predicting the incidence or types of 
OIs in HIV-infected populations have also been investigated. 
In an evaluation of the profile of OIs in HIV‑infected persons 
living in Australia,[101] PJP was clearly, the most commonly 
diagnosed condition in people of all country/region of birth 
except for individuals born in sub-Saharan Africa. Those 
born in sub-Saharan Africa had an increased risk of TB and 
cryptococcosis but a decreased risk of PJP and esophageal 
candidiasis compared to individuals born in Australia even 
after adjusting for length of stay in Australia. TB risk was 
also higher among those born in Asia-Pacific and other 
low-income countries, but the risk of various types of OIs was 
similar for HIV-infected patients born in Australia and other 
industrialized countries. According to Del Amo et al.,[102] TB 
accounted for 27% of the initial episodes of AIDS-related OIs 
in Africans but 5% in non-Africans while PJP was the initial 
AIDS-related condition in 34% of non-Africans but 17% for 
Africans. In Netherlands, it was reported that compared to 
patients from Western Europe, Australia, and New Zealand, 
patients of sub‑Saharan African origin had a significantly 
lower risk for PJP both at the time of HIV diagnosis and during 
follow-up while in care after adjusting for confounders.[98] The 
authors suggested that differences in genetic susceptibility 
may partially explain the lower PJP incidence in the African 
patients.
The introduction of HAART was associated with substantial 
reduction in the incidence of OIs both in HICs and LMICs. 
To some extent, regarding percentage decline in the burden 
of OIs following the introduction of HAART, the findings of 
this review suggest a somewhat more impressive impact in 
HICs, which has apparently enjoyed earlier, wider, and more 
durable access to HAART. Beyond the earlier introduction of 
HAART in HICs compared to most LMICs, antiretroviral drug 
options are better in HICs. The wide availability of PIs in HICs 
possibly lays credence to this. In 12,574 HIV cohorts from 13 
HICs in Europe and North America, 85.6% of patients initiating 
HAART between mid-1990s and 2000 were commenced on a 
PI-based regimen.[14] At the end of 2010 <5% of HIV-infected 
individuals in LMICs (excluding South and Central America) 
were receiving PI-containing regimens mainly as second-line 
ART.[19] However, the comparison of the impact of HAART on 
the magnitude of OIs between HICs and LMICs was further 
complicated by the observation that studies accessing the 
impact of HAART on OIs in LMICs lagged behind those of 
HICs by 5 years or more. In the event of possible differences 
in HAART-induced decline in OI incidence between people 
of diverse socioeconomic settings, it becomes necessary to 
unravel any other key factor(s) that may affect the risk of OIs 
in patients receiving HAART.
HIV-infected patients on HAART who have poorer 
socioeconomic living conditions have been found to have 
higher risk of OIs. Iroezindu et al.[96] found that poor 
household income was an independent predictor of OIs among 
Nigerian patients on HAART. Badri et al.[103] also reported 
that low socioeconomic status was significantly associated 
with incident TB during HAART in South Africa. While 
poor living conditions may not be a critical problem in HICs, 
failure to determine the effect of poverty on the development 
of OIs in the era of HAART in LMICs would be a fundamental 
oversight.
The findings of this review have important regional and global 
public health implications in the management of HIV/AIDS. 
First, the efficacy of HAART in reducing OI morbidity and 
its attendant mortality in PLHIV has been shown beyond 
reasonable doubt irrespective of socioeconomic differences. 
However, despite emerging evidence of the significant 
burden of noninfective morbidity in PLHIV in a number of 
studies.[104,105] OIs continue to be a problem even in the era of 
HAART as the burden of disease is still considerable in several 
populations. Since the somewhat more impressive percentage 
decline in OI burden reported in HICs compared to LMICs may 
not be unconnected with the earlier, wider, and more durable 
access to HAART, it re‑emphasizes the need for intensification 
of the scaling up of ART in resource-limited settings.
The findings of this study should be interpreted in the light 
of its strengths and limitations. One of the strengths of this 
review is that the period considered spanned the entire three 
decades of the HIV/AIDS epidemic. Moreover, the studies 
included in this review involved patients in all the continents 
of the world. In addition, the majority of the studies reviewed 
reported incidence rates which adjusted for population 
size and period under exposure thereby allowing for some 
reasonable comparisons between studies with different 
sample sizes. A major limitation of this review regarding the 
overall incidence or prevalence of OIs is the differences in the 
definition of diseases selected for inclusion as OI in the various 
studies. While some studies investigated only AIDS‑defining 
conditions, others included non‑AIDS‑defining OIs depending 
on the peculiarities of their geographical region. Second, 
there were relatively fewer studies from LMICs (especially 
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sub-Saharan Africa) that performed active follow-up over 
long periods of time compared to HICs. In addition, in some 
countries or regions, only one or two studies published in 
English were found, and these studies may not necessarily be 
representative of the picture in the entire country or region. 
As a result of the unavailability of information regarding 
chemoprophylaxis for OIs in the majority of studies, this 
review was unable to assess the possible impact of OI 
chemoprophylaxis on the changes in OI incidence following 
the introduction of HAART. The lack of diagnostic capacity 
for certain OIs such as MAC and CMV diseases in several 
resource-limited settings also calls for caution while drawing 
conclusions on the actual incidence or prevalence of these 
OIs in LMICs.
Conclusion
This review found that the magnitude of HIV-related OIs was 
substantial in both HICs and LMICs before the introduction 
of HAART, but LMICs appeared to have higher OI incidence 
or prevalence. There were also disparities in the types of 
OIs frequently reported in each socioeconomic setting. It 
was further shown that the introduction of HAART led to 
substantial reductions in the overall incidence of OIs with 
somewhat more impressive impact in HICs. As our clinical 
concerns increasingly shift towards the growing burden of 
noninfective complications of HIV and its treatment, let 
us not erronously conclude that OIs have become a thing 
of the past. According to Brooks et al.,[106] “OIs are here to 
stay, and they will continue to demand our attention for the 
foreseeable future. They continue to occur among patients who 
are unaware of their HIV infection and among patients who, 
despite awareness of their HIV infection, remain unlinked to 
care, or if receiving care, are unable to assess optimal ART 
for several reasons.” Incidentally, nearly all the factors that 
perpetuate OIs in the era of HAART as observed by Brooks 
et al.[106] are much more prevalent in LMICs. Should it then 
be appropriate to say that the achievements of the scaling up 
of ART in resource-limited settings may face a major threat 
in the face of these undermining factors? If this happens, any 
seeming disparity in the magnitude of HIV-associated OIs 
and the benefits of HAART between HICs and LMICs may 
inadvertently be widened in the era of HAART.
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